Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis

Abstract Background Tolvaptan slows kidney function decline in patients with autosomal dominant polycystic kidney disease (ADPKD) who are at risk of rapid progression. Given that treatment requires commitment to long-term use, we evaluated the effects of tolvaptan discontinuation on the trajectory o...

Descripció completa

Dades bibliogràfiques

Autors principals:	Michael Lioudis, Xiaolei Zhou, Eric Davenport, Sasikiran Nunna, Holly B. Krasa, Dorothee Oberdhan, Ancilla W. Fernandes
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2023-06-01
Col·lecció:	BMC Nephrology
Matèries:	Autosomal dominant polycystic kidney disease (ADPKD) Tolvaptan Glomerular filtration rate Kidney volume Clinical trial Treatment
Accés en línia:	https://doi.org/10.1186/s12882-023-03247-6
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!